Cipla Limited — Important, 20-01-2025: Updates

The USFDA conducted an inspection at Cipla's manufacturing facility for Medispray in Kundaim, Goa. The inspection, which took place from the 14th to the 20th of January, resulted in one observation noted in Form 483. Cipla is committed to working closely with the USFDA to comprehensively address this observation within the stipulated timeframe. This development may impact the operational aspects of Medispray, and investors should monitor the situation closely for potential implications on production activities and regulatory compliance. The company's proactive approach could mitigate risks associated with the observation while ensuring continued focus on quality standards.